Nautilus Biotechnolgy, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $226.2M
- Price
- $1.84
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.37%
- Volume
- 968.1K
Quote data as of 6:10 AM ET
About
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Quick stats
Shares outstanding127.1M
Computed float41.1M
Float sourceUnknown
Cash runway (months)20.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001808805
Websitehttps://www.nautilus.bio
AI Summary
AI-generated23h agominorneutralotherNautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
Nautilus Biotechnology announced it will report its second quarter 2026 financial results before market open on Tuesday, July 28, 2026.
Management will host a conference call at 8:30 a.m. Eastern Time to discuss the results, business developments, and outlook.
The company is a development-stage life sciences firm focused on creating a platform technology for proteome analysis.